Having followed the development of gene therapy over the past 15 years, I am excited to see it coming of age, with the first FDA approved therapy, Kymriah™, made available on August 30th of this year.  Because gene therapies offer a potential cure, they represent a significant advancement that is invaluable to patients.  However along with this innovation comes a considerable barrier – extremely high cost.

There are 1500 more therapies in the pipeline, and considering their potential cost, it will be crucial for manufacturers, payers, and other stakeholders to work together and devise innovative solutions to help patients have access to these treatments.  The article below touches upon financing approaches that may be considered.  Regardless, payers will need to be more flexible in how they evaluate these therapies, while manufacturers will need to engage with payers earlier in the development process to ensure maximum patient access.